EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Xiaofeng Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Characteristic Innovation Project of the Guangdong Province Education Department, Scientific Research Projects in Colleges and Universities of Guangzhou Education Bureau.
Abstract (Originalsprache)
Empty spiracles homeobox 2 (EMX2) is initially identified as a key transcription factor that plays an essential role in the regulation of neuronal development and some brain disorders. Recently, several studies emphasized that EMX2 could as a tumor suppressor, but its role in human clear cell renal cell carcinoma (ccRCC) remains unclear. In the present study, we investigated the role and underlying mechanism of EMX2 in the regulation of ccRCC progress. Our results demonstrated that EMX2 expression was markedly decreased in ccRCC tissues and cell lines, and low EMX2 expression predicted the poor prognosis of ccRCC patients. In addition, forced expression of EMX2 significantly inhibited the cell growth, migration, and invasion in vitro, as well as ccRCC tumor growth in nude mice, via, at least in part, regulating Akt/FOXO3a pathway. In detail, EMX2 could attenuate the phosphorylation levels of Akt and FOXO3a, and increase FOXO3a expression without affecting total Akt expression in vivo and in vitro. Meanwhile, shRNA‐mediated knockdown of FOXO3a expression could obviously attenuate the effects of EMX2 on cell growth, migration, invasion, and tumor growth. Furthermore, EMX2 could significantly attenuate the interaction between Akt and FOXO3a. Taken together, our results demonstrated that EMX2 could inhibit ccRCC progress through, at least in part, modulating Akt/FOXO3a signaling pathway, thus representing a novel role and underlying mechanism of EMX2 in the regulation of ccRCC progress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Guangdong Key Laboratory of Urology, Guangzhou, China.
- Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou, China.
- Guangzhou Institute of Urology, Guangzhou, China.
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
ORCID-Profile: Xiaolu Duan
Förderung
- National Natural Science Foundation of China
- Characteristic Innovation Project of the Guangdong Province Education Department
- Scientific Research Projects in Colleges and Universities of Guangzhou Education Bureau
Zitieren
APA
Zhou, X., Dong, S., Zhou, Y., He, Z., Zhang, Z., Liao, L., Zou, B., Zheng, X., Peng, K., & Duan, X. (2024). EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23700
Vancouver
Zhou X, Dong S, Zhou Y, He Z, Zhang Z, Liao L, et al. EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23700
BibTeX
@article{Zhou2024,
author = {Zhou, Xiaofeng and Dong, Sicheng and Zhou, Yuhao and He, Zhiqing and Zhang, Zhixiong and Liao, Liqiong and Zou, Bangyu and Zheng, Xiaopeng and Peng, Kaoqing and Duan, Xiaolu},
title = {EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23700}
}
EUVIMED